Results 81 to 90 of about 70,554 (222)
Head &Neck, EarlyView.ABSTRACT Background Quality of life (QoL) in head and neck cancer (HNC) is influenced by complex biopsychosocial factors, yet few longitudinal studies have examined these relationships immediately post‐treatment. Methods In this prospective study, 232 patients newly diagnosed with primary HNC completed psychometric assessments, clinical interviews, and
Haley Deamond +18 more
wiley +1 more source
Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. [PDF]
, 2019 PurposeTo date, evidence for tissue epidermal growth factor receptor (EGFR) overexpression as a biomarker for anti-EGFR therapies has been weak. We investigated the genomic landscape of EGFR amplification in blood-derived cell-free tumor DNA (cfDNA ...
Fanta, Paul T +13 more
core +1 more source
Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. [PDF]
, 2016 Tumour resistance to radiotherapy remains a barrier to improving cancer patient outcomes. To overcome radioresistance, certain drugs have been found to sensitize cells to ionizing radiation (IR).
Adams, Stephen R +10 more
core +1 more source
Head &Neck, EarlyView.ABSTRACT Background Unknown primary cancer in the head and neck presents a difficult surgical treatment dilemma. Patients with squamous cell carcinoma of unknown primary (SCCUP) typically present with an enlarging neck mass found on biopsy but with no indication of primary site on diagnostic exams such as flexible laryngoscopy, CT, MRI, and/or PET/CT ...
Nikhil Bellamkonda +5 more
wiley +1 more source
Antibody-antigen interactions: What is the required time to equilibrium? [PDF]
, 2010 The use of antibodies is widespread in many areas including in-vivo and in-vitro diagnostics, quantitative analysis in research laboratories and as therapeutic substances.
Hanna Bjö +2 more
core +1 more source
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo. [PDF]
, 2015 Epidermal growth factor receptor (EGFR) inhibitors have demonstrated efficacy in squamous cell carcinoma of the head and neck (SCCHN). In addition to EGFR, other ErbB family members are expressed and activated in SCCHN. Afatinib is an ErbB family blocker
Baum, Anke +8 more
core +1 more source
International Journal of Cancer, EarlyView.What's New? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken +20 more
wiley +1 more source
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. [PDF]
, 2015 BackgroundThis retrospective study aims to investigate the activity of retreatment with anti-EGFR-based therapies in order to explore the concept of clonal evolution by evaluating the impact of prior activity and intervening time interval.MethodsEighty ...
Eng, C +20 more
core +2 more sources
Cetuximab Induces Eme1-Mediated DNA Repair: a Novel Mechanism for Cetuximab Resistance
Neoplasia: An International Journal for Oncology Research, 2014 Overexpression of the epidermal growth factor receptor (EGFR) is observed in a large number of neoplasms. The monoclonal antibody cetuximab/Erbitux is frequently applied to treat EGFR-expressing tumors.
Agnieszka Weinandy +11 more
doaj +1 more source
Experimental Hematology & Oncology, 2020 Objective To explore the efficacy of primary chemoradiation with cisplatin versus cetuximab with respect to HPV/p16 and smoking statuses. Methods We retrospectively reviewed patients from our center with locally advanced non-nasopharyngeal head and neck ...
Il Seok Daniel Jeong +11 more
doaj +1 more source